ArticleRespiratory medicine case reports2025
Metastatic lung pleomorphic giant cell carcinoma treated with multimodality systemic anti-cancer treatment, a two-year journey: A case report.
Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pleomorphic giant cell carcinoma (PGCC) of the lung is a rare and aggressive subtype of non-small cell lung cancer with limited therapeutic options. We present a case of a 50-year-old male with stage IV, PD-L1-negative PGCC managed through a sequential multimodal treatment approach. Case presentation: A 50 year old gentleman, known to be a heavy smoker, presented with metastatic disease involving the lungs, bone, and lymph nodes. He received dual immunotherapy with Nivolumab and Ipilimumab, achieving a partial response before progression. Subsequent MAID chemotherapy provided transient disease control, followed by Carboplatin-Paclitaxel, which yielded a more durable response. With additional radiotherapy for brain metastases, the patient achieved an overall survival of 30 months. Conclusion: This case underscores the rarity and therapeutic complexity of metastatic PGCC and highlights the potential survival benefit of an adaptive, multidisciplinary treatment strategy integrating immunotherapy, chemotherapy, and targeted radiotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.